Introduction: targeting different pathways to prevent tumor cell development.
Kantarjian
Hagop M
HM
Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. hkantarj@mdanderson.org
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015195:Drug Design; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors